How Unnatural Amino Acids Are Making Antimicrobial Peptides More Powerful and Stable

Incorporating non-natural amino acids into antimicrobial peptides (AMPs) addresses key limitations that have hindered their clinical development: protease degradation, production challenges, safety concerns, and activity retention. Non-natural amino acids with unique structures and properties can optimize AMP-target interactions, expand functional capabilities, and improve stability against enzymatic breakdown. The review covers how these modifications can enhance antibacterial, antiviral, and anticancer properties of AMPs while overcoming the barriers to large-scale application.

Comprehensive narrative review examining published research on the use of non-natural amino acids to modify antimicrobial peptides. The review covers the sources, mechanisms of action, and current limitations of AMPs, then focuses on how non-natural amino acid incorporation addresses these challenges.

Antibiotic resistance is one of the greatest global health threats, and antimicrobial peptides are among the most promising alternatives to conventional antibiotics. However, natural AMPs are quickly broken down by enzymes in the body, limiting their therapeutic use. Non-natural amino acid modifications offer a path to making these peptides more stable, potent, and clinically viable — potentially creating a new generation of drugs to combat resistant bacteria, viruses, and even cancer.

With antibiotic resistance projected to cause 10 million deaths annually by 2050 if unchecked, antimicrobial peptides represent one of the most important classes of alternative antimicrobials under development. The strategy of incorporating non-natural amino acids addresses the primary reason AMPs have not yet achieved widespread clinical success — their vulnerability to enzymatic degradation. This approach is part of a broader trend in peptide therapeutics of using chemical modifications to transform promising but unstable natural molecules into viable drugs.

As a review article, no new experimental data is presented. The abstract discusses general principles without quantifying the degree of improvement from specific non-natural amino acid modifications. The practical challenges of manufacturing peptides with non-natural amino acids at scale — including cost and regulatory considerations — are acknowledged but not deeply explored.